Tesamorelin
Used to shrink deep belly fat. A GHRH analog that's FDA-approved for HIV-associated lipodystrophy and used off-label for visceral fat reduction.
Tesamorelin: Used to shrink deep belly fat. A GHRH analog that's FDA-approved for HIV-associated lipodystrophy and used off-label for visceral fat reduction. Tesamorelin is an FDA-approved GH-axis peptide that specifically targets visceral fat, the deep belly fat around organs.
Tesamorelin is an FDA-approved GH-axis peptide that specifically targets visceral fat, the deep belly fat around organs. Daily injection. Slow burn, but the visceral fat reduction is well-documented.
FDA-approved drug products containing this substance are available. Compounded versions are not FDA-approved.
Yes for HIV indication. Off-label use outside that scope is common but not on-label.
Who it's for
- →Users targeting visceral (deep abdominal) fat specifically
- →Older adults wanting GH-axis support without HGH
- →People with elevated visceral fat on DEXA
What to expect
- Week 1
Sleep deepens. Nothing visual yet.
- Week 4
Subtle waist measurement changes for users tracking carefully.
- Week 8
Visceral fat reduction visible on imaging in clinical trials.
Looking at Tesamorelin? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for Tesamorelin.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
GHRH analog with structural modifications that resist proteolytic breakdown. Binds the same GHRH receptor as Sermorelin and CJC, with longer activity window. Specifically reduces visceral fat through GH-mediated lipolysis.
Dosing protocol
Stacks well with
Stack essentials
Side effects
When NOT to use
- ⚠Active malignancy
- ⚠Pituitary disorders
- ⚠Pregnancy / nursing
Bloodwork to monitor
- • IGF-1 baseline + every 6 weeks
- • Fasting glucose
Common mistakes
- • Expecting subcutaneous fat loss (it primarily targets visceral)
- • Stopping before week 12 (the response builds over months)
- • Not measuring visceral fat at baseline so you can't tell if it worked
What it actually is
Tesamorelin is a stabilised analog of growth hormone releasing hormone and the only compound in the GH-axis section of this catalog with a current FDA approval. It is sold as Egrifta for reducing excess visceral abdominal fat in people with HIV-associated lipodystrophy. The current US formulations are EGRIFTA SV and EGRIFTA WR; they differ in strength, are not substitutable, and the original 1 mg presentation is discontinued. Everything else it is used for — general belly fat reduction in people without HIV — is off-label, and that off-label use is the majority of what happens outside a clinic.
It binds the GHRH receptor on the pituitary and triggers release of your own growth hormone, which then raises IGF-1. In the trials the observed pattern was reduced visceral adipose tissue without significant loss of abdominal subcutaneous fat. That is a measured body-composition outcome rather than proof that the receptor selectively targets visceral fat cells, and it is the source of most disappointment with the drug: it does not directly reduce the fat you can pinch, though phase 3 participants did report an improved abdominal appearance as visceral fat fell.
Forms, and which is which
Manufacturer products with assured identity and potency. They are different strengths and NOT substitutable; the original 1 mg EGRIFTA is discontinued.
Verdict: The only forms with known contents — check which one a prescription is for.
Buyer reconstitutes. Tesamorelin is unstable enough that handling and storage genuinely matter, and there is no way to verify what arrived.
Verdict: Cheaper, unverified, and the stability question is real.
Pairs a GHRH analog with a ghrelin-receptor agonist. Coherent in the same way the CJC-1295 pairing is, and equally untested as a combination.
Verdict: Reasonable theory, no combination trial.
The same receptor, a much shorter half-life, and no current approval. Not equivalent — tesamorelin's stabilisation is what got it through trials.
Verdict: Related, and not a drop-in replacement.
What it is claimed to do, graded
This is the approved indication and it is backed by phase 3 randomised trials with imaging endpoints, not self-report. Roughly 15-18% visceral adipose tissue reduction over 26 weeks in the pivotal trials.
Two large randomised phase 3 studies found significant improvement in both measures. Read the claim as those specific endpoints.
Randomised evidence in HIV-associated fatty liver supports it. Smaller than the visceral fat programme.
It does not meaningfully do this, and this is the single most common reason people are disappointed by it.
Lean body mass did rise by roughly 1.2 to 1.3 kg in the pivotal studies, which is a real measured result. It is not the same as muscle hypertrophy, and strength was not demonstrated.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • Actually FDA-approved, with phase 3 imaging-endpoint evidence — rare in this catalog
- • The visceral fat effect is measurable and real, not inferred from a surrogate
- • Stimulates your own pituitary rather than replacing growth hormone, so release keeps its pulsatile pattern — though that is not a ceiling: at 26 weeks 47% of treated participants had IGF-1 above +2 SDS and 36% above +3 SDS, which is why IGF-1 monitoring is required
- • The trial programme means side effects and monitoring are genuinely known
- • Expensive as the pharmacy product, and off-label use is not covered
- • The effect reverses when you stop — visceral fat returns
- • Takes months: judging it before week 12 is judging it too early
- • Raises IGF-1 and can worsen glucose tolerance
- • Needs baseline imaging or a waist measurement to know whether it worked, and most people skip that
When to stop
- • Any immediate hypersensitivity reaction
- • Fasting glucose or A1C rising out of range, or any new or worsening vision change — rapid glucose improvement can worsen diabetic retinopathy
- • IGF-1 persistently and markedly elevated on monitoring
- • Persistent numbness or tingling in the hands
- • Swelling that does not settle after the first weeks
- • Any new cancer diagnosis
- • Acute critical illness — the label says discontinuation should be considered
Interactions
Growth hormone opposes insulin, so glucose control can drift. Trials tracked this specifically.
Exogenous growth hormone suppresses the axis this works through, and stacks the same side effects.
The label warning that matters: growth hormone inhibits 11-beta-HSD1 and can lower cortisol, so someone on replacement steroid may need a higher maintenance or stress dose. Pharmacologic steroid doses separately blunt the growth response.
Directly opposing mechanisms, so efficacy is undermined. An antagonism to manage with a specialist, not a demonstrated safety contraindication.
The label advises monitoring these, since growth hormone can alter their clearance.
Is this for you?
- • People with HIV-associated lipodystrophy working with a prescriber
- • Anyone whose visceral fat has been measured at baseline, so there is something to compare against
- • You want to lose subcutaneous fat — it does not do that
- • You have active cancer or a pituitary disorder
- • You are pregnant or nursing
- • You expect to judge it in the mirror — visceral fat is what changes, and it is measured on a scan
The one number
Sources for the claims above
- Drug profile and approval basis
- GHRH analogue for HIV-associated lipodystrophy
- Efficacy and safety in people with HIV on integrase inhibitors
- Pooled phase 3 analysis of visceral fat, lipid and lean mass outcomes
Drug & supplement interactions
- ⚠Glucocorticoids and oral estrogen may reduce response
- ⚠Insulin requirements may shift in diabetics
- ⚠Cytochrome P450 substrates: tesamorelin may modestly increase metabolism, disclose all medications
Community patterns
New to Tesamorelin? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about Tesamorelin or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is Tesamorelin?+
Is Tesamorelin FDA approved?+
Is Tesamorelin legal?+
Is Tesamorelin banned by WADA?+
Are you still natty after taking Tesamorelin?+
Do doctors prescribe Tesamorelin?+
What's the typical dose of Tesamorelin?+
What are the side effects of Tesamorelin?+
How long until Tesamorelin starts working?+
What can you stack with Tesamorelin?+
Where do people get Tesamorelin?+
Tesamorelin vs CJC-1295 (no DAC), which is better?+
Tesamorelin vs AOD-9604, which is better?+
Tesamorelin vs Ipamorelin, which is better?+
Common questions about Tesamorelin
Tracked alongside Tesamorelin
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in GH-axis
Recombinant human growth hormone, the protein itself, not a peptide that nudges your body to make more. Highest legal-risk compound in this catalog.
Oral ghrelin mimetic. Bumps GH and IGF-1 without injections. Strong appetite stimulation is the trade-off.
Bumps your natural growth-hormone pulses without hitting cortisol or prolactin. A selective GH secretagogue.
Pairs with Ipamorelin to amplify your natural growth-hormone pulses. A GHRH analog whose 'no-DAC' version stays short-acting on purpose.